Ariel E. Birnbaum

518 total citations
25 papers, 284 citations indexed

About

Ariel E. Birnbaum is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Ariel E. Birnbaum has authored 25 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Otorhinolaryngology. Recurrent topics in Ariel E. Birnbaum's work include Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (8 papers) and HER2/EGFR in Cancer Research (6 papers). Ariel E. Birnbaum is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (8 papers) and HER2/EGFR in Cancer Research (6 papers). Ariel E. Birnbaum collaborates with scholars based in United States, Brazil and France. Ariel E. Birnbaum's co-authors include Neal Ready, Howard Safran, Melissa Eliot, Brock C. Christensen, Thomas Ng, Karl T. Kelsey, Humera Khurshid, Dominique S. Michaud, Thomas A. DiPetrillo and Carmen J. Marsit and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ariel E. Birnbaum

25 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ariel E. Birnbaum United States 8 119 118 60 60 39 25 284
Naoki Izawa Japan 9 132 1.1× 189 1.6× 109 1.8× 83 1.4× 31 0.8× 58 363
Jim Vasselli United States 8 121 1.0× 365 3.1× 47 0.8× 34 0.6× 23 0.6× 10 406
Andy Blake-Haskins United States 8 126 1.1× 379 3.2× 63 1.1× 30 0.5× 21 0.5× 13 419
Bo Wei China 8 130 1.1× 71 0.6× 50 0.8× 59 1.0× 71 1.8× 30 315
Binnari Kim South Korea 11 122 1.0× 141 1.2× 71 1.2× 66 1.1× 71 1.8× 29 289
Juergen Krauss Germany 7 47 0.4× 116 1.0× 21 0.3× 53 0.9× 12 0.3× 14 167
Atsushi Yagishita Japan 9 212 1.8× 92 0.8× 146 2.4× 120 2.0× 90 2.3× 21 413
Yaping Xu China 13 358 3.0× 236 2.0× 120 2.0× 59 1.0× 47 1.2× 44 523
Junmiao Wen China 11 209 1.8× 124 1.1× 97 1.6× 50 0.8× 36 0.9× 33 336
Cihang Bao China 11 112 0.9× 110 0.9× 104 1.7× 169 2.8× 118 3.0× 19 398

Countries citing papers authored by Ariel E. Birnbaum

Since Specialization
Citations

This map shows the geographic impact of Ariel E. Birnbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ariel E. Birnbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ariel E. Birnbaum more than expected).

Fields of papers citing papers by Ariel E. Birnbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ariel E. Birnbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ariel E. Birnbaum. The network helps show where Ariel E. Birnbaum may publish in the future.

Co-authorship network of co-authors of Ariel E. Birnbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Ariel E. Birnbaum. A scholar is included among the top collaborators of Ariel E. Birnbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ariel E. Birnbaum. Ariel E. Birnbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sun, Lova, Jérôme Fayette, Sébastien Salas, et al.. (2024). Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.. Journal of Clinical Oncology. 42(16_suppl). 6012–6012. 7 indexed citations
3.
Cho, Byoung Chul, Omid Hamid, Xinhua Zhu, et al.. (2024). A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.. Journal of Clinical Oncology. 42(16_suppl). 6038–6038. 4 indexed citations
4.
Cirauqui, Beatriz, Sébastien Salas, William William, et al.. (2023). Abstract CT164: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207. Cancer Research. 83(8_Supplement). CT164–CT164. 6 indexed citations
5.
Le, Xiuning, Benedito A. Carneiro, David S. Hong, et al.. (2022). innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS6100–TPS6100. 5 indexed citations
6.
Hong, David S., Jérôme Fayette, Ariel E. Birnbaum, et al.. (2021). 930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors. Annals of Oncology. 32. S816–S816. 1 indexed citations
7.
Misra, Sumathi, et al.. (2020). ‘I Can't Eat, Speak, or Kiss My Wife. It's Half a Life, but at Least I'm Still Alive.’ Navigating the Sequelae of Head and Neck Cancer (TH307). Journal of Pain and Symptom Management. 59(2). 407–408. 1 indexed citations
8.
He, Aiwu Ruth, Roger B. Cohen, Crystal S. Denlinger, et al.. (2019). First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. The Oncologist. 24(9). e930–e942. 54 indexed citations
9.
Hepel, Jaroslaw T., K.L. Leonard, Howard Safran, et al.. (2016). Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study. International Journal of Radiation Oncology*Biology*Physics. 96(5). 1021–1027. 30 indexed citations
10.
Birnbaum, Ariel E., et al.. (2015). Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas. Cureus. 7(12). e403–e403. 21 indexed citations
11.
Ward, Robert C., Ariel E. Birnbaum, Bassam I. Aswad, & Terrance T. Healey. (2014). Solitary pulmonary nodule: pleuropulmonary synovial sarcoma.. PubMed. 97(5). 40–3. 2 indexed citations
12.
Khurshid, Humera, Thomas A. DiPetrillo, Thomas Ng, et al.. (2012). A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 2. 56–56. 10 indexed citations
13.
Birnbaum, Ariel E., Ritesh Rathore, Priscilla Merriam, et al.. (2012). Cetuximab, Paclitaxel, Carboplatin, and Radiation for Head and Neck Cancer. American Journal of Clinical Oncology. 37(2). 162–166. 5 indexed citations
14.
Rathore, Ritesh, et al.. (2012). Trial of anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) in patients with EGFR-expressing recurrent/metastatic non-small cell lung cancer (NSCLC) and solid tumors.. Journal of Clinical Oncology. 30(15_suppl). e13124–e13124. 1 indexed citations
15.
Birnbaum, Ariel E., Howard Safran, Thomas A. DiPetrillo, et al.. (2011). Pathologic Response After Neoadjuvant Carboplatin and Weekly Paclitaxel for Early-Stage Lung Cancer: A Brown University Oncology Group Phase II Study. Journal of Thoracic Oncology. 6(8). 1432–1434. 5 indexed citations
16.
Birnbaum, Ariel E., Ritesh Rathore, Harry Wanebo, et al.. (2010). Cetuximab, Paclitaxel, Carboplatin, and Radiation For Head and Neck Cancer. American Journal of Clinical Oncology. 33(2). 144–147. 14 indexed citations
17.
Berz, David, Katherine Faricy‐Anderson, Sherry Weitzen, Ariel E. Birnbaum, & Gary M. Strauss. (2010). Do race and ethnicity predict survival in metastatic non-small cell lung cancer?. PubMed. 93(10). 299–302. 5 indexed citations
18.
Ng, Thomas, Ariel E. Birnbaum, Jacques P. Fontaine, et al.. (2009). Pneumonectomy After Neoadjuvant Chemotherapy and Radiation for Advanced-Stage Lung Cancer. Annals of Surgical Oncology. 17(2). 476–482. 6 indexed citations
19.
20.
Birnbaum, Ariel E. & Neal Ready. (2005). Gefitinib therapy for non-small cell lung cancer. Current Treatment Options in Oncology. 6(1). 75–81. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Izawa Breakdown of academic impact, for papers by Jim Vasselli Breakdown of academic impact, for papers by Andy Blake-Haskins Breakdown of academic impact, for papers by Bo Wei Breakdown of academic impact, for papers by Binnari Kim Breakdown of academic impact, for papers by Juergen Krauss Breakdown of academic impact, for papers by Atsushi Yagishita Breakdown of academic impact, for papers by Yaping Xu Breakdown of academic impact, for papers by Junmiao Wen Breakdown of academic impact, for papers by Cihang Bao
Rankless by CCL
2026